Immunovant, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Immunovant, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2018 to 2023.
  • Immunovant, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending June 30, 2024 was $686K, a 22.9% decline year-over-year.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $472M, a 566% increase from 2022.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $70.9M, a 64.6% decline from 2021.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $200M, a 47.8% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $472M +$402M +566% Apr 1, 2023 Mar 31, 2024 10-K 2024-05-29
2022 $70.9M -$129M -64.6% Apr 1, 2022 Mar 31, 2023 10-K 2024-05-29
2021 $200M -$183M -47.8% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-22
2020 $383M +$236M +161% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-08
2019 $147M +$111M +313% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-01
2018 $35.6M Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.